Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Public ClinicalTrials.gov record NCT06036836. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) \[Cohort A\] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants proficient in mismatch repair (pMMR) endometrial cancer (EC) \[Cohort B\].
Study identification
- NCT ID
- NCT06036836
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 163 participants
Conditions and interventions
Interventions
- favezelimab/pembrolizumab Biological
- pembrolizumab Biological
- lenvatinib Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 28, 2023
- Primary completion
- Mar 11, 2026
- Completion
- Mar 11, 2026
- Last update posted
- Mar 18, 2026
2023 – 2026
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale-New Haven Hospital-Yale Cancer Center ( Site 0643) | New Haven | Connecticut | 06510 | — |
| Dana-Farber Cancer Institute ( Site 0642) | Boston | Massachusetts | 02215 | — |
| Rutgers Cancer Institute of New Jersey ( Site 0635) | New Brunswick | New Jersey | 08903 | — |
| Duke Cancer Institute ( Site 0641) | Durham | North Carolina | 27710 | — |
| Cleveland Clinic Main ( Site 0639) | Cleveland | Ohio | 44195 | — |
| St. Luke's University Health Network ( Site 0636) | Bethlehem | Pennsylvania | 18015 | — |
| UPMC Hillman Cancer Center ( Site 0644) | Pittsburgh | Pennsylvania | 15232 | — |
| UT Southwestern Medical Center-CRO-Simmons Comprehensive Cancer Center ( Site 0645) | Dallas | Texas | 75390-9179 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06036836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06036836 live on ClinicalTrials.gov.